If you missed Friday’s exclusive Q&A with Codexis story, here’s a more visual way to get an inside look at the enzyme engineering company via this illuminating slide guide they just released. From synthetic biology, the acceleration of enzyme discovery and engineering, the commercialization engine, their customer base, case studies, partnerships, and more.
In California, Codexis, Inc., enzyme engineering company, provided a business update with their Sustainable Manufacturing business demonstrating “remarkable growth, as we significantly executed against the large enzyme orders we received from Pfizer to support its COVID-19 antiviral therapeutic candidate” as well as strong results in the faster-to-market food sector, including enzyme sales for Tate & […]
In California, Codexis, Inc., a leading enzyme engineering company reported record product revenue of $14.7M, up 227% YOY, that drove their product gross margin to a new high of 71%. Product revenues were primarily driven by the sale of enzymes used to manufacture branded pharmaceutical products. “Codexis had an extraordinarily strong second quarter, with record […]
In California, enzyme engineering company, Codexis, is raising its guidance for 2021, following the receipt of a binding purchase order for up to $13.9 million of a proprietary high performance enzyme product from an undisclosed global pharmaceutical company. The majority of this order was not included in Codexis’ prior guidance for 2021; accordingly, the Company […]
In California, enzyme engineering company Codexis reported total revenues for Q1 2021 at $18.0 million, an increase of 23% from $14.7 million in Q1 2020. On a segment basis, $14.2 million in revenue was from the Performance Enzymes segment and $3.8 million was from Novel Biotherapeutics. Product revenues increased 101% to $10.2 million in Q1 […]
In California, Codexis’s 2020 full year product gross margin exceeds 50% for the first time in company’s history and expects 2021 to be strong as well with projected total revenues of $82-85 million and product revenues of $36-39 million, especially thanks to its enzyme engineering platform, CodeEvolver. “Codexis delivered strong results in 2020, despite the […]
Who’s in Hot Water? Some of the Usual Suspects get into the usual trouble. We note that EPA missed the 2021 Renewable Volume Obligation deadline, and Growth Energy threatens a lawsuit. Really. We get tired of reporting on the industry having to (almost annually) sue the government to compel compliance to the law. It’s a […]
We frequently hear that the only constant is change and in today’s bioeconomy world, we see this lived out all the time. Companies come and go but some evolve, transform, and change. Today we focus on some of these pivotal pivots and the transformations with these leaders who live and breathe change to survive. Some […]
Codexis is a leading protein engineering company that applies its technology to the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. Codexis CEO John Nicols gave this illuminating presentation on the company’s progress, […]
Codexis is a leading protein engineering company that applies its technology to the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. This illuminating presentation looks at the company’s progress promise, and most recent […]
